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SUMMARY – Th e aim of the study was to assess the role of serum osteoprotegerin (OPG) as a 
biomarker in patients with aortic valve stenosis (AS) in relation to heart failure and symptomatic 
status. Th is was a case control study, which included 51 patients with AS and 39 control subjects. At 
the time of study enrolment, detailed medical history was obtained and all subjects underwent physi-
cal examination, chest x-ray and echocardiography. OPG levels were measured in all subjects, and 
serum N-terminal of the pro b-type natriuretic peptide (NT pro BNP) levels were determined in 
patients with AS. Serum OPG levels were elevated in patients with AS compared to control subjects 
(p=0.001). Patients with heart failure due to AS had elevated serum OPG levels in comparison to 
patients without heart failure (p=0.001). A signifi cant correlation between OPG and symptomatic 
status was observed in all patients with AS (p<0.001), however, it was not the case in patients without 
heart failure (p=0.425). Th ere was a positive correlation between OPG and NT pro BNP concentra-
tions with objective signs of heart failure on chest x-ray (p<0.001). Negative correlation of OPG 
concentrations with aortic valve area was present (p<0.040), as well as with left ventricular ejection 
fraction (p<0.001). Serum OPG could be a valuable biomarker in the evaluation of severity of calcifi ed 
AS and serve as an additional indicator besides clinical presentation and echocardiography in the as-
sessment of surgical treatment or aortic valve replacement.
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Introduction
Calcifi ed aortic valve stenosis (AS) is not just a de-
generative process, as was previously thought. In the 
last decade, its infl ammatory and atheromatous nature 
has been emphasized and it is considered a potentially 
modifying disease1,2. Calcifi ed aortic valve disease is 
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the most common cause of aortic valve replacement in 
the western world, and increases in the prevalence with 
aging, aff ecting 2%-3% of the population by the age of 
65 years3.
Due to variability in the assessment of hemody-
namic deterioration and diffi  culties in recognizing 
worsening of symptoms, the need for new serum bio-
markers to assess the severity of AS has become an 
issue of utmost importance. In severe AS, the most 
studied biochemical marker is N-terminal of the pro 
b-type natriuretic peptide (NT pro BNP), which is the 
inactive fragment of B-type natriuretic peptide (BNP) 
and is released from the myocardium in response to 
pressure and volume overload4-6. Clinical studies have 
shown that NT pro BNP has particular signifi cance in 
determining the timing of surgery in asymptomatic 
patients with severe AS7, that symptomatic patients 
have a higher concentration of NT pro BNP than 
those without symptoms, and that asymptomatic pa-
tients who develop symptoms shortly after measuring 
NT pro BNP have a higher concentration than those 
that remain asymptomatic5,8.
Osteoprotegerin (OPG) and the OPG/RANKL/
RANK system are members of the tumor necrosis fac-
tor (TNF) receptor family9. Th ey regulate the activity 
of osteoblasts and osteoclasts, and directly aff ect endo-
thelial and vascular smooth muscle cells10-12. Inhibition 
of vascular calcifi cation mediated through OPG in 
animal and in vitro studies13,14 has not been confi rmed 
in clinical research15-17. Furthermore, numerous studies 
have demonstrated association of elevated OPG values 
and degenerative aortic valve disease18-21.
Th erefore, it is conceivable that circulating levels of 
osteoprotegerin are increased in patients with severe 
calcifi ed AS and in patients with heart failure as a com-
plication of severe AS. Th us, OPG could represent a 
potential biomarker to determine optimal timing for 
surgical treatment in these patients and could provide 
relevant clinical information in addition to clinical pre-
sentation, NT pro BNP levels and echocardiography.
Th e aim of this study was to examine the value of 
OPG levels in relation to development of heart failure 
in patients with symptomatic severe AS, to character-
ize the association of OPG with left ventricular (LV) 
function and remodeling, and to determine the signifi -




In this pair-matched case-control study, we com-
pared a well-defi ned population of 51 patients with 
AS and preserved renal function but without coronary 
artery disease, ischemic cerebrovascular or peripheral 
vascular disease, and 39 control subjects without AS. 
Th e study participants were recruited from the popula-
tion of patients hospitalized at the Department of 
Cardiology, Osijek University Hospital Center, for di-
agnostic evaluation of severe calcifi ed AS.
Th is study complied with the Declaration of Hel-
sinki and was approved by the Ethics Committee of 
the Osijek University Hospital Center. A written in-
formed consent was obtained from each subject prior 
to inclusion in the study.
Patient population
Th e inclusion criteria for the study group included 
severe calcifi ed aortic valve stenosis diagnosed by stan-
dard echocardiography. Severe AS was defi ned as the 
aortic valve area <1 cm2 and mean systolic gradient >50 
mm Hg. Left ventricular ejection fraction (LVEF) was 
also assessed according to European guidelines22, 
whereby patients with preserved systolic function had 
ejection fractions ≥50%, and those with impaired sys-
tolic function had ejection fractions <50%. Control 
group subjects had no evidence of valvular disease, 
valve calcifi cation, or coronary artery disease, as as-
sessed by standard methods of echocardiography and 
exercise testing (by Bruce protocol).
Patients with a history of the following conditions 
were excluded from the study: previous myocardial in-
farction, coronary artery disease diagnosed with coro-
nary angiography (presence of coronary artery stenosis 
>50%) or exercise testing, moderate and severe aortic 
and mitral valve insuffi  ciency (defi ned by vena con-
tracta >0.3 cm), history of coronary surgery, atrial fi -
brillation, macrovascular complications of diabetes, 
severe renal insuffi  ciency (serum creatinine >170 
μmol/L), severe ischemic peripheral vascular disease 
(patients with no concomitant leg symptoms), history 
of stroke, severe osteoporosis (on therapy), therapy 
with corticosteroids, immunosuppressive agents, hor-
mone replacement therapy, and systemic diseases (his-
tory data). Exclusion criteria were identical for the 
study and control groups.
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Patients with aortic valve stenosis were further di-
vided into three subgroups depending on the develop-
ment of heart failure and symptoms: symptomatic AS 
and heart failure (n=29); symptomatic AS without 
heart failure (n=15); asymptomatic AS without heart 
failure (n=14). Heart failure was diagnosed on clinical 
presentation according to NYHA classifi cation, chest 
x-ray (defi ned by the presence of redistribution on pul-
monary vessels and broad vascular pedicle) and mea-
surement of NT pro BNP serum levels (with cut-off  
level >900 pg/mL for the diagnosis of heart failure).
All participants (patients and controls) were as-
sessed for conventional cardiovascular risk factors, 
which were defi ned as follows: arterial hypertension: 
blood pressure >140/90 mm Hg or medically treated; 
hypercholesterolemia: serum cholesterol >5.2 mmol/L 
or medically treated; diabetes mellitus: overnight fast-
ing serum glucose >7.0 mmol/L or medically treated; 
smoking history; positive family history of coronary 
artery disease; obesity: and body mass index (BMI) 
>25 kg/m2. Both groups, with and without AS, were 
age and gender matched and were closely aligned with 
respect to the risk factors which could otherwise alter 
serum OPG levels (Table 1).
with symptoms of severe AS and heart failure (breath-
lessness, intolerance eff ort, night cough, paroxysmal 
nocturnal dyspnea, hemoptysis), chest pain or syncope 
were classifi ed as symptomatic, while asymptomatic 
patients were those with no symptoms whatsoever. Pa-
tients were then admitted to the Department of Car-
diology, Osijek University Hospital Center for routine 
diagnostic preoperative work-up of severe calcifi ed AS, 
which included coronary angiography and aortogra-
phy. Th us, the presence of associated coronary artery 
disease was excluded (coronary artery disease was de-
fi ned by the presence of coronary artery stenosis 
>50%).
Echocardiographic examination included trans-
thoracic examination in both groups. Examinations 
were performed according to the European Society of 
Cardiology (ESC) guidelines, especially the European 
Association of Echocardiography/American Society 
of Echocardiography recommendations22. To evaluate 
AS, we measured maximum (AV Pg max) and mean 
(AV Pg mean) transvalvular pressure gradients, eff ec-
tive orifi ce area (EOA) using linear equation and aor-
tic valve area (AVA) using planimetry. Th e parameters 
of left ventricular geometry, function and afterload 
were analyzed using standard methods. Th e parame-
ters included left ventricular (LV) end-diastolic and 
end-systolic volume, LVEF, stroke volume, stroke vol-
ume index, interventricular septum, left ventricular 
mass, and left ventricular mass index. Left ventricular 
parameters were assessed using the two-dimensional 
left parasternal long axis view. Measurements were 
performed by two-dimensional ultrasound Siemens 
Acuson 70, with cardiac probe P4-2.
Peripheral venous blood samples of 10-12 mL were 
collected between 7 and 8.30 a.m., after at least 12-
hour fasting. Serum levels of glucose, creatinine, total 
cholesterol, high- and low-density lipoprotein choles-
terol, and triglycerides were measured. Serum levels of 
OPG and NT pro BNP were measured with enzyme 
linked immunosorbent assays (Biomedica Medizin-
produkte GmbH & Co., Germany).
Statistical analysis
Results were analyzed using descriptive statistical 
analysis. Signifi cance was declared at a two-sided 0.05 
level, unless otherwise specifi ed. Statistical analyses 
were performed using SPSS for Windows software 
(version 16.0, SPSS Inc., Chicago IL, USA).
Table 1. Baseline characteristics of study group 








Mean age (yrs) 68.3725 66.7692 0.396**









41 (80.4%) 33 (84.6%) 0.417**
Diabetes 17 (33.3%) 14 (35.9%) 0.803**
Hyperlipidemia 42 (82.4%) 29 (74.4%) 0.372**
Smoking status 15 (29.4%) 13 (33.3%) 0.696**
BMI 28.3753 26.6500 1.000***
*Mann-Whitney U test; **Student’s t-test; ***χ2-test; BMI = body 
mass index
Methods
At the time of inclusion, detailed medical history 
was obtained and physical examination, electrocardio-
gram (ECG) and chest x-ray were performed. Patients 
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Diff erence between two independent variables was 
analyzed by Student’s t-test for parametric analysis, 
while χ2-test and Mann-Whitney test were used for 
nonparametric analysis. Nonparametric analysis was 
used for smaller sample of examined variables, or, in 
our case, it was used for the analysis of serum OPG 
levels depending on the presence of heart failure. Non-
parametric analysis was also used in the case of asym-
metric distribution of the variables analyzed.
Normal distribution of numerical variables was 
tested by Kolmogorov-Smirnov test.
Spearman’s correlation coeffi  cients were computed 
to estimate the magnitude of the association between 
the variables of interest, in this case between serum 
OPG and NT pro BNP.
Results
Serum OPG concentrations in patients 
with aortic stenosis and control group
Table 2 shows serum OPG levels of pair-matched 
patients and controls. Th e mean value of serum OPG 
in patients with AS was signifi cantly higher than in 
the control group (6.54 pmol/L vs. 4.89 pmol/L; 
p=0.001). Regarding cardiovascular risk factors, no 
statistically signifi cant diff erences were recorded be-
tween these two groups (Table 1).
failure compared with serum OPG levels in the AS 
group without heart failure (p=0.001) (Table 2). Th ere 
was a strong positive correlation between OPG and 
NT-pro BNP levels in patients with AS (ρ=0.796, 
p<0.001) (Table 3).
Table 2. Patients with aortic stenosis according to presence 






Patients with AS 6.54 4.90 -9.32
<0.001











AS = aortic stenosis; OPG = osteoprotegerin; *Mann-Whitney U 
test
Table 3. Association of serum OPG concentration 
and NT pro BNP in patients with aortic stenosis and 













of NT pro BNP
0.775 <0.001
OPG = osteoprotegerin; NT pro BNP = N-terminal brain natri-
uretic peptide
Serum OPG concentrations in patients with AS 
in relation to heart failure and serum NT pro BNP
Within the study group (with AS), serum OPG 
levels were signifi cantly elevated in patients with heart 
Serum OPG concentrations in relation to symptomatic 
status of patients with aortic stenosis
Patients with aortic valve stenosis were divided 
into three subgroups depending on the development 
of heart failure and symptoms: symptomatic AS and 
heart failure (n=29); symptomatic AS without heart 
failure (n=15); and asymptomatic AS without heart 
failure (n=14) (Table 4). A signifi cant correlation be-
Table 4. Association of serum OPG concentration 
and symptomatic status in patients with aortic stenosis 
and serum OPG concentration in AS patients without 



















Symptomatic 15 5.27 4.62-6.31
0.425
Asymptomatic 14 4.94 4.60-5.72
AS = aortic stenosis; OPG = osteoprotegerin
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tween serum concentrations of OPG and symptom-
atic status was observed in all patients with AS (ρ=-
0.554, p<0.001), however, there was no signifi cant cor-
relation of OPG concentration and symptomatic sta-
tus in patients without heart failure (p=0.425) (Table 
4). In addition, there was a positive correlation between 
serum concentrations of OPG and NT pro BNP with 
signs of heart failure on chest x-ray (ρ=0.667, p<0.001 
and ρ=0.775, p<0.001, respectively) (Table 3).
Serum OPG concentrations in relation to parameters 
of echocardiography (AVA, AV Pg mean, AV Pg max, 
LVEF) in patients with aortic stenosis
Th e relationship between OPG and parameters of 
echocardiography is shown in Table 5. A statistically 
signifi cant negative relationship between serum con-
centrations of OPG and aortic valve area was observed 
(r=-0.321, p<0.040). Th ere was no correlation between 
serum OPG concentrations and medium or maximum 
aortic transvalvular pressure gradients. A negative cor-
relation between serum OPG concentrations and LVEF 
(r=-0.571, p<0.001) was recorded and serum OPG was 
elevated in patients with impaired LVEF (EF <50%).
tients with heart failure, when compared to patients 
without heart failure.
OPG in relation to LVEF in patients with aortic valve 
stenosis according to OPG values on Y-axis and LVEF 
>50% and <50% on X-axis
Th e relationship between serum concentration of 
OPG and LVEF >50% or <50% in patients with aortic 
valve stenosis is shown graphically on Boxplot analyses 
(Fig. 2). It is shown that OPG had signifi cantly higher 
Table 5. Analysis of OPG serum concentration in relation 
to parameters of echocardiography (AVA, AV Pg mean, 
AV Pg max and LVEF) in patients with aortic stenosis
Osteoprotegerin concentration





AVA (<1 cm2) -0.321 0.040
AV Pg mean (50 mm Hg) 0.189 0.317
AV Pg max (>80 mm Hg) -0.004 0.976
LVEF (cut-off  value for reduced 
EF 50%)
-0.571 <0.001
AS = aortic stenosis; AVA = aortic valve area; AV Pg mean = aortic 
valve transvalvular middle gradient; AV Pg max = aortic valve 
transvalvular maximum gradient; LVEF = left ventricular ejection 
fraction
OPG in relation to heart failure in patients with aortic 
valve stenosis according to OPG values on Y-axis 
and presence or absence of heart failure on X-axis
Th e relationship between serum concentration of 
OPG and the presence or absence of heart failure is 
shown graphically on Boxplot analyses (Fig. 1). It is 
shown that OPG has signifi cantly higher values in pa-
Fig. 1. Osteoprotegerin (OPG) level in relation to heart 
failure in patients with aortic valve stenosis, and presence 
or absence of heart failure.
Fig. 2. Osteoprotegerin (OPG) level in relation to left 
ventricular ejection fraction (LVEF) in patients with 
aortic valve stenosis and LVEF >50% or LVEF <50%.
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values in patients with LVEF <50% than in those with 
LVEF >50.
Discussion
Early-stage degenerative aortic valve disease re-
mains asymptomatic for many years, but when symp-
toms occur, the disease has often already progressed to 
severe stages4. With the occurrence of symptoms, 90% 
of patients with untreated severe AS have a life expec-
tancy of less than 10 years23, and if AS is presenting 
with heart failure, the mortality is more than 50% 
within a year24. Th e purpose of biomarkers in AS is as-
sessment of disease severity, thus allowing prognosis of 
disease outcome and potentially assisting in deciding 
on timely surgical procedure. Given the above, the ob-
jective of this study was to assess the value of serum 
OPG concentration as a biomarker in patients with 
calcifi ed AS in relation to heart failure and symptoms.
In a study performed by Akat et al.21 elevated se-
rum OPG concentrations were present in patients 
with calcifi ed AS, however, patients with AS in this 
study were not divided into groups depending on the 
existence of heart failure. Our results not only revealed 
elevation of serum OPG concentrations in patients 
with calcifi ed AS when compared to controls but also 
a statistically signifi cant increase in serum OPG con-
centrations in patients with AS and heart failure com-
pared to patients without heart failure. Previous re-
ports investigated OPG levels in patients with isch-
emic and dilated cardiomyopathy and showed elevated 
serum levels in these patients25, 26, however, without 
reporting whether or not they developed heart failure. 
Unlike the former studies, our results showed elevation 
in serum concentrations of OPG in symptomatic pa-
tients with heart failure, and its increase with progres-
sion of NYHA stage, which could be a direct conse-
quence of its increased myocardial release due to car-
diac failure.
In all patients with AS, a signifi cant correlation of 
OPG levels and symptomatic status was present, but 
no correlation was observed in the subgroup of pa-
tients without heart failure (both symptomatic and 
asymptomatic). Th is can be explained by the fact that 
patients with symptoms of dyspnea or heart failure 
had increased levels of OPG as a result of increased 
myocardial release, whereas in patients with other AS 
symptoms (angina and syncope) there were no signs of 
heart failure and therefore no signifi cant diff erences in 
serum OPG concentrations were present. Also, the es-
timated severity of AS does not always correlate with 
the onset of symptoms and as a result, many patients 
with severe AS may be asymptomatic or in fact they do 
not recognize or choose to ignore their symptoms. 
Considering that those are high-risk patients and re-
quire close monitoring, it is diffi  cult to assess the right 
time for surgical treatment. Presently, the recommen-
dations for treating these patients, based on the ESC 
cardiac guidelines are in favor of conservative treat-
ment and follow-up27. Th erefore, serum OPG could be 
an additional marker for early screening of patients 
who need urgent aortic valve replacement, along with 
echocardiography monitoring, and already established 
elevated NT pro BNP levels.
A strong positive correlation of OPG and NT pro 
BNP exists in patients with heart failure due to AS28. 
Th is was also confi rmed in our study, where a statisti-
cally signifi cant positive correlation between serum 
OPG concentrations and NT pro BNP was observed 
in symptomatic patients with heart failure. Also, we 
established a positive correlation of serum OPG and 
NT pro BNP concentrations with the objective signs 
of heart failure present on chest x-ray. Apparently, el-
evated serum concentrations of both biomarkers of 
heart failure refl ect objectively the state of lung con-
gestion. Increase in these two biomarkers probably oc-
curs as a result of diff erent pathophysiological mecha-
nisms that lead to heart failure. Th e fact that serum 
OPG is increased in patients with heart failure may be 
related to OPG as a predictor of increased cardiovas-
cular mortality28,29.
Results on the correlation between serum OPG 
concentrations and AS severity in relation to the pa-
rameters of echocardiography are so far contradicto-
ry28,30,31. In our study, a negative correlation of serum 
OPG concentrations and AVA was observed, that is, a 
statistically signifi cant increase in serum OPG con-
centrations was present in patients with smaller AVA. 
Th is could be explained by the presence of more severe 
calcifi cations in smaller AVA, and in that case, elevated 
serum OPG could be due to an anti calcifi ed eff ect or 
compensatory mechanisms to limit the calcifi cation 
process32,33. Th ere was no association of transvalvular 
gradients and OPG concentrations since our patients 
had impaired ejection fraction as opposed to previous 
studies where positive correlation of serum OPG lev-
els and middle transvalvular gradient was present in 
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patients with AS and preserved LV systolic func-
tion30,31.
Our study results showed a strong negative correla-
tion between LVEF and OPG concentrations, mean-
ing that patients with worse ejection fraction had ele-
vated OPG levels. Th is is consistent with previous 
studies, which demonstrated a signifi cant negative 
correlation between serum concentrations of OPG 
and LVEF in the general population and in symptom-
atic patients with AS29,34.
Th is study had several limitations. It was a cross-
sectional study, so we could not establish causal rela-
tionship, and the number of patients was relatively 
small. Furthermore, there are some issues in using 
OPG as a biomarker in patients with calcifi ed AS that 
need to be addressed. Th e presence of severe renal fail-
ure36, acute exacerbation of coronary disease37, severity 
of coronary artery disease on angiography38 and other 
causes of heart failure17 could conceal the real cause of 
elevated serum OPG concentrations. However, in all 
of these patients, there is a positive correlation between 
serum OPG and total cardiovascular disease mortali-
ty28,29. Presently, there is no exact reference value when 
OPG is considered signifi cantly elevated indicating a 
worse prognostic outcome, but we demonstrated that 
its serum concentration increased with the degree of 
heart failure defi ned according to NYHA stage and 
correlated positively with the NT pro BNP biomarker, 
which is considered a good indicator of the status of 
symptomatic AS6.
Conclusion
In conclusion, elevated serum OPG levels are as-
sociated with the existence of calcifi cation and stenosis 
of the aortic valve, and with the development of heart 
failure in patients with severe calcifi ed AS. Th us, it 
would be possible to use serum OPG in the evaluation 
of severity of calcifi ed AS, and as an auxiliary indicator 
in the assessment of surgical treatment or aortic valve 
replacement in addition to clinical presentation and 
echocardiography.
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Sažetak
SERUMSKA VRIJEDNOST OSTEOPROTEGERINA U BOLESNIKA 
S KALCIFICIRAJUĆOM AORTNOM STENOZOM U OVISNOSTI O ZATAJENJU SRCA
S. Makarović, Z. Makarović, I. Bilić-Ćurčić, J. Milas-Ahić, I. Mihaljević, M. Franceschi i T. Jukić
Cilj ove studije bio je ocijeniti ulogu osteoprotegerina (OPG) kao biljega u bolesnika sa stenozom aortnog srčanog zali-
ska u odnosu na prisutne simptome kao i stupanj srčanog zatajenja. U studiju je bio uključen 51 bolesnik s aortnom stenozom 
(AS) i 39 kontrolnih ispitanika. Prije uključenja u studiju uzeta je detaljna anamneza, učinjen je fi zikalni pregled, rentgenska 
snimka srca i pluća te ehokardiografi ja. OPG je određen u svih ispitanika, a N-terminalni nastavak pro b-tipa natriuretskog 
peptida (NT pro BNP) bio je određen u bolesnika s AS. OPG je bio povišen u bolesnika s AS u odnosu na kontrolne ispita-
nike (p=0,001). Bolesnici sa srčanim zatajenjem zbog AS imali su povišene razine OPG-a u odnosu na bolesnike bez srčanog 
zatajenja (p=0,001). Značajna korelacija između OPG-a i simptomatskog statusa bila je zapažena u svih bolesnika s AS 
(p<0,001), ali to nije bio slučaj u bolesnika bez srčanog zatajenja (p=0.425). Zabilježena je i pozitivna korelacija između 
koncentracije OPG-a i NT pro BNP-a s objektivnim znakovima srčanog zatajenja na rentgenskoj snimci srca i pluća 
(p<0,001). Također je opažena negativna korelacija OPG-a i areje aortnog zaliska (p<0,040) te istisne frakcije lijeve klijetke 
(p<0,001). OPG bi mogao predstavljati vrijedan biljeg u procjeni težine kalcifi cirane AS te bi mogao poslužiti kao dodatni 
indikator prilikom odlučivanja o kirurškom liječenju ili zamjeni aortnog zaliska, naravno, uz kliničku prezentaciju i ehokar-
diografi ju.
Ključne riječi: Osteoprotegerin – krv; Aortni srčani zalistak, stenoza – patologija; Kalcinoza – krv; Srčano zatajivanje; Biomar-
keri – krv; Natriuretični peptidi; Prognoza
